Clinical trials: Metastatic Neoplasm
Carcinoma, Renal Cell
Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma
To investigate safety and efficacy of single agent sunitinib malate as first-line systemic therapy in Chinese patients with metastatic renal cell carcinoma.
- Trial name
- MRCC RCC (NCT00706706)
- Testing
- Sunitinib Malate (SU011248)
- Where
- 11 sites in China
- Volunteers
- 105 people
- Sponsor
- Pfizer
Metastatic/Advanced Renal Cell Carcinoma
Evaluation Of The Impact Of A Call Center In Management Of Metastatic And/Or Advanced Renal Cell Carcinoma Patients Treated With Sunitinib (Sutent) In First Line
100 patients with metastatic and/or advanced renal cell carcinoma treated with sunitinib (Sutent) will be inclued and followed with standard care plus a call center Principal assumption : the proportion of patients presenting…
- Trial name
- RENACALL (NCT02187042)
- Testing
- Best supportive care, call center
- Where
- 13 sites in France
- Volunteers
- 70 people
- Sponsor
- Pfizer
Gastric Cancer
FLX475 Combined With Pembrolizumab in Patients With Advanced or Metastatic Gastric Cancer
This clinical study is a Phase 2, open-label study to assess the efficacy, safety profile of FLX475 combined with pembrolizumab in patients with advanced or metastatic gastric cancer.
- Trial name
- NCT04768686
- Testing
- FLX475, Pembrolizumab
- Where
- 10 sites in South Korea
- Volunteers
- 20 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Metastatic Prostate Cancer
Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer
The purpose of this study is to find the recommended doses of dasatinib and docetaxel given in combination to men with metastatic hormone refractory prostate cancer and to assess the pharmacokinetic interactions between the 2…
- Trial name
- NCT00439270
- Testing
- Dasatinib, Docetaxel
- Where
- 5 sites in United States
- Volunteers
- 49 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Triple Negative Breast Cancer
Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer
This study will investigate the safety and efficacy of TIL therapy in patients with metastatic TNBC who have progressed on at least one and no more than three prior systemic anticancer therapies.
- Trial name
- NCT04111510
- Testing
- Tumor infiltrating lymphocytes (TIL) LN-145
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Yale University
Carcinoma, Renal Cell, Kidney Disease
Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer
Determine time-to-progression (TTP) for an escalating dose schedule for subjects with progressive metastatic renal cell carcinoma treated with sorafenib
- Conditions
- Carcinoma, Renal Cell, Kidney Disease, Kidney Cancer
- Trial name
- NCT00854620
- Testing
- Sorafenib
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Stanford University
Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm
Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer
This phase I trial studies the side effects and best dose of vandetanib and everolimus when given together in treating patients with cancer that has spread to other places in the body.
- Conditions
- Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm, Refractory Malignant Neoplasm
- Trial name
- NCT01582191
- Testing
- Everolimus, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 123 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer
A Study of LY2584702 in Solid Tumors
The purpose of this study is to assess the safety and tolerability of LY2584702 in Japanese patients with advanced and/or metastatic solid tumors for which no proven effective therapy exists.
- Trial name
- NCT01241461
- Testing
- LY2584702
- Where
- Japan
- Volunteers
- 9 people
- Sponsor
- Eli Lilly and Company
Spinal Metastases
Stereotactic Radiosurgery (SRS) for Spine Metastases
This study will evaluate the most effective radiation dose. Patients will be randomized (like flipping a coin) to receive either low dose stereotactic radiotherapy (defined as "14 Gy") or high dose stereotactic radiotherapy…
- Trial name
- SRS (NCT00593320)
- Testing
- Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Washington University School of Medicine
Pancreatic Cancer, Metastatic Pancreatic Cancer
Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer
Pancreatic cancer is one of the leading causes of cancer deaths in the United States with limited treatment options, especially for those patients with metastatic disease.
- Trial name
- NCT04820179
- Testing
- Cabozantinib + Atezolizumab
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Arizona
Metastatic Breast Cancer
Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression
This is a multicenter, open-label, single-arm Phase II study designed to evaluate the effect of T-DM1 on the duration of corrected QT (QTc) interval in patients with HER2-positive locally advanced or metastatic breast cancer and…
- Trial name
- NCT00943670
- Testing
- pertuzumab, Trastuzumab emtansine [Kadcyla]
- Volunteers
- 51 people
- Sponsor
- Genentech, Inc.
Metastatic Prostate Cancer
Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer
This Phase 3 study will target approximately 100 men over age 18 who have a biochemical relapse or other evidence of relapse of prostate cancer after primary treatment. The purpose of this study is to: A.
- Trial name
- NCT02260817
- Testing
- 11C-choline Injection
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Global Isotopes, LLC d/b/a Zevacor Molecular
Metastatic Gastrointestinal Carcinoid Tumor, Pulmonary Carcinoid Tumor
Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma
This phase II trial is studying how well CCI-779 works in treating patients with progressive metastatic neuroendocrine tumors. Drugs used in chemotherapy, such as CCI-779, work in different ways to stop tumor cells from dividing…
- Conditions
- Metastatic Gastrointestinal Carcinoid Tumor, Pulmonary Carcinoid Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma
- Trial name
- NCT00093782
- Testing
- temsirolimus, laboratory biomarker analysis
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Ductal Adenocarcinoma
Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma
The main objective of this trial is to assess the efficacy of onvansertib in combination with nanoliposomal irinotecan (nal-IRI), leucovorin, and fluorouracil (5-FU) for treatment of participants with histologically confirmed…
- Trial name
- NCT04752696
- Testing
- Onvansertib, Nanoliposomal irinotecan, Leucovorin
- Where
- 6 sites in United States
- Volunteers
- 41 people
- Sponsor
- Cardiff Oncology
Metastatic Pancreatic Adenocarcinoma
Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)
This is a phase 3 study to evaluate the efficacy of ibrutinib in combination with nab-paclitaxel and gemcitabine for the first line treatment of patients with metastatic pancreatic adenocarcinoma.
- Trial name
- NCT02436668
- Testing
- Ibrutinib, Gemcitabine, Nab-paclitaxel
- Where
- 86 sites in United States, Belgium and 6 more
- Volunteers
- 430 people
- Sponsor
- Pharmacyclics LLC.
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth and by blocking blood flow to the tumor.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00397488
- Testing
- sunitinib malate
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Liver Metastases, Colorectal Neoplasms
Phase 3 Trial of Litx™ Plus Chemotherapy vs. Chemotherapy Only Treating Colorectal Cancer Patients With Recurrent Liver Metastases
The purpose of the study is to assess the overall survival and progression free survival of patients treated with Litx™ + chemotherapy versus chemotherapy alone in the treatment of Colorectal Cancer with recurrent liver…
- Conditions
- Liver Metastases, Colorectal Neoplasms, Neoplasm Metastasis, Neoplasm Recurrence, Local
- Trial name
- NCT00440310
- Testing
- Talaporfin sodium, Percutaneous placement of device in liver metastases, Interstitial light emitting diodes
- Where
- 57 sites in Austria, Bosnia and Herzegovina and 11 more
- Volunteers
- 483 people
- Sponsor
- Light Sciences Oncology
Thyroid Cancer
To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer
The purpose of this study is to give patients with medullary thyroid cancer either 300mg/day or 150mg/day vandetanib and compare how well each dose affects how their cancer responds.
- Trial name
- NCT01496313
- Testing
- 300mg vandetanib, 150mg vandetanib
- Where
- 30 sites in United States, Czechia and 7 more
- Volunteers
- 81 people
- Sponsor
- Sanofi
Colorectal Cancer, Colorectal Tumors
An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread
The purpose of this study is to investigate treatment with nivolumab in combination with trametinib with or without ipilimumab in participants with previously treated cancer of the colon or rectum that has spread.
- Conditions
- Colorectal Cancer, Colorectal Tumors, Colorectal Carcinoma, Colorectal Neoplasm
- Trial name
- CheckMate 9N9 (NCT03377361)
- Testing
- Nivolumab, Trametinib, Ipilimumab
- Where
- 47 sites in United States, Argentina and 8 more
- Volunteers
- 325 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Breast Cancer
A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
This was a multi-institutional, open-label, single-arm, Phase II study of trastuzumab emtansine (T-DM1) administered by intravenous (IV) infusion to patients with human epidermal growth factor receptor 2 (HER2)-positive…
- Trial name
- NCT00509769
- Testing
- Trastuzumab emtansine [Kadcyla]
- Where
- 40 sites in United States
- Volunteers
- 112 people
- Sponsor
- Genentech, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.